Rituximab in Refractory Primary Membranous Nephropathy

Status Completed

Clinical Trial Summary

Primary membranous nephropathy (PMN), an autoimmune disease mostly associated with anti-phospholipase-A2-receptor (PLA2R) antibodies, is one of the most common causes of nephrotic syndrome in adults. In 30% to 40% of all cases, patients with PMN undergo spontaneous remission with conservative approaches. Corticosteroids, alkylating agents and calcineurin inhibitors are recommended treatment options in persistent disease activity despite supportive therapies. Nevertheless, patients with refractory disease constitute an important clinical aspect of PMN, and uncontrolled proteinuria may culminate in rapid progression to end-stage renal disease. In recent years, several studies demonstrated the efficacy of rituximab as a treatment option in patients with refractory PMN; however, data regarding daily clinical practice of this agent is still needed. Therefore, we conducted a study using our registry data to evaluate the efficacy and safety of rituximab in patients with refractory PMN.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03880643
Study type	Observational
Source	Istanbul University
Contact
Status	Completed
Phase
Start date	November 1, 2018
Completion date	September 30, 2019

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01129557` - Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease	Phase 4
Completed	`NCT00199628` - Research Network for Neonatal Diseases Induced by Tissular Fetomaternal Alloimmunization
Active, not recruiting	`NCT05656963` - The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
Completed	`NCT04145440` - Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)	Phase 1/Phase 2
Terminated	`NCT04154787` - Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy	Phase 2
Completed	`NCT00404794` - A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis	Phase 3
Not yet recruiting	`NCT05797051` - Application of Hyperspectral Imaging in the Diagnosis of Glomerular Diseases
Completed	`NCT00135967` - Mycophenolate Mofetil in Membranous Nephropathy	Phase 2/Phase 3
Completed	`NCT00843856` - Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis	Phase 4
Recruiting	`NCT01282073` - Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy	Phase 3
Recruiting	`NCT05914155` - Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome	Phase 3
Completed	`NCT00135954` - Treatment of Patients With Idiopathic Membranous Nephropathy	Phase 3
Completed	`NCT01610492` - A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy	Phase 2
Active, not recruiting	`NCT03018535` - Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy	Phase 3
Completed	`NCT00404833` - Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental	Phase 3
Withdrawn	`NCT01762852` - Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy	Phase 2